> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Sarepta Scraps Next-Gen Duchenne Drug
- URL: https://www.fdaweb.com/sarepta-scraps-next-gen-duchenne-drug/
- Published: 2024-11-07T12:00:00.000Z
- Updated: 2026-09-14T14:46:24.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5158146

Sarepta says it is discontinuing the development of SRP-5051 (vesleteplirsen), an investigational, next-generation peptide conjugated phosphorodiamidate morpholino oligomer for treating patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping. The decision was based on FDA feedback about the therapy’s risk-benefit, according to the company, particularly reports of abnormally low magnesium (hypomagnesemia) that continued to be reported in patients taking the therapy.

Earlier this year, Sarepta [reported](https://www.biospace.com/sarepta-therapeutics-announces-positive-data-from-part-b-of-momentum-a-phase-2-study-of-srp-5051-in-patients-with-duchenne-muscular-dystrophy-amenable-to-skipping-exon-51?ref=fdaweb.com) positive data from Part B of the Phase 2 MOMENTUM study, which assessed vesleteplirsen in patients aged 8 to 21 years who are amenable to exon 51 skipping. The company noted at the time that cases of hypomagnesemia had previously been identified and that this was “managed and monitored” during the trial.

During an 11/6 earnings call, company executives noted that the cases continued to be seen including in some patients who had discontinued treatment. The company said it was also told by FDA that the accelerated approval pathway was not a viable option for vesleteplirsen based on the current data.